Abstract
Vancomycin, a glycopeptide antibiotic, has long been a drug of choice for life-threatening Gram-positive bacterial infections. Vancomycin confers its antibacterial activity by inhibiting bacterial cell wall biosynthesis. However, over the time, vancomycin has also been rendered ineffective by vancomycin-resistant bacteria (VRB). These bacteria developed resistance to it by alteration of cell wall precursor from D-Ala-D-Ala to D-Ala-D-Lac (vancomycin-resistant Enterococci, VRE), which leads to manifold reduction in the binding constant and results in the loss of antibacterial activity. Herein, we report various vancomycin–sugar analogs, based on a simple design rationale, which exhibit increased binding affinity to VRB, thereby resensitizing VRB to vancomycin. Optimized vancomycin–sugar conjugate exhibited 150-fold increase in affinity for N,N′-diacetyl-Lys-D-Ala-D-Lac compared with vancomycin. This improved binding affinity was also reflected in its antibacterial activity, wherein the MIC value was brought down from 750 to 36 μM against VRE (VanA phenotype). To further sensitize against VRE, we appended lipophilic alkyl chain to optimized vancomycin–sugar conjugate. This lipophilic–vancomycin–sugar conjugate was >1000-fold (MIC=0.7 μM) and 250-fold (MIC=1 μM) more effective against VanA and VanB strains of VRE, respectively, compared with vancomycin. Therefore, this synthetically simple approach could lead to the development of new generation of glycopeptide antibiotics, which can be clinically used to tackle VRB infections.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Taubes G. The bacteria fight back. Science 321, 356–361 (2008).
Bush K. et al. Tackling antibiotic resistance. Nat. Rev. Microbiol. 9, 894–896 (2011).
Wenzel R. P., Edmond M. B. Managing antibiotic resistance. N. Engl. J. Med. 343, 1961–1963 (2000).
Kahne D., Leimkuhler C., Lu W., Walsh C. T. Glycopeptide and lipoglycopeptide antibiotics. Chem. Rev. 105, 425–448 (2005).
Yang Z., Vorpagel E. R., Laskin J. Experimental and theoretical studies of the structures and interactions of vancomycin antibiotics with cell wall analogues. J. Am. Chem. Soc. 130, 13013–13022 (2008).
Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect. Dis. 1, 147–155 (2001).
McComas C. C., Crowley B. M., Boger D. L. Partitioning the loss in vancomycin binding affinity for D-Ala-D-Lac into lost H-bond and repulsive lone pair contributions. J. Am. Chem. Soc. 125, 9314–9315 (2003).
Walsh C. T., Fisher S. L., Park I. S., Prahalad M., Wu Z. Bacterial resistance to vancomycin: five genes and one missing hydrogen bond tell the story. Chem. Biol. 3, 21–28 (1996).
Uppu D. S. S. M. et al. Polymers with tunable side-chain amphiphilicity as non-hemolytic antibacterial agents. Chem. Commun. 49, 9389–9391 (2013).
Ghosh C. et al. Small molecular antibacterial peptoid mimics: the simpler the better!. J. Med. Chem. 57, 1428–1436 (2014).
Hu Y. et al. Lipidated peptidomimetics with improved antimicrobial activity. ACS Med. Chem. Lett. 3, 683–686 (2012).
Choi S. et al. De novo design and in vivo activity of conformationally restrained antimicrobial arylamide foldamers. Proc. Natl Acad. Sci. USA 106, 6968–6973 (2009).
Lai X. Z. et al. Ceragenins: cholic acid-based mimics of antimicrobial peptides. Acc. Chem. Res. 41, 1233–1240 (2008).
Moraski G. C., Thanassi J. A., Podos S. D., Pucci M. J., Miller M. J. One step syntheses of nitrofuranyl benzimidazoles that are active against multi-drug resistant bacteria. J. Antibiot. 64, 667–671 (2011).
O'Daniel P. I. et al. Discovery of a new class of non-β-lactam inhibitors of penicillin-binding proteins with Gram-positive antibacterial activity. J. Am. Chem. Soc. 136, 3664–3672 (2014).
Nguyen K. T. et al. Genetically engineered lipopeptide antibiotics related to A54145 and daptomycin with improved properties. Antimicrob. Agents Chemother. 54, 1404–1413 (2010).
Ashford P. A., Bew S. P. Recent advances in the synthesis of new glycopeptide antibiotics. Chem. Soc. Rev. 41, 957–978 (2012).
Yoshida O. et al. Novel semi-synthetic glycopeptide antibiotics active against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci (VRE): doubly modified water-soluble derivatives of chloroorienticin B. Bioorg. Med. Chem. Lett. 12, 3027–3031 (2002).
Nakama Y. et al. Discovery of a novel series of semisynthetic vancomycin derivatives effective against vancomycin-resistant bacteria. J. Med. Chem. 53, 2528–2533 (2010).
Mu Y. Q., Nodwell M., Pace J. L., Shaw J. P., Judice J. K. Vancomycin disulfide derivatives as antibacterial agents. Bioorg. Med. Chem. Lett. 14, 735–738 (2004).
Chen L. et al. Vancomycin analogues active against vanA-resistant strains inhibit bacterial transglycosylase without binding substrate. Proc. Natl Acad. Sci. USA 100, 5658–5663 (2003).
Blizzard T. A. et al. Antibacterial activity of G6-quaternary ammonium derivatives of a lipophilic vancomycin analogue. Bioorg. Med. Chem. Lett. 12, 849–852 (2002).
Nagarajan R., Schabel A. A., Occolowitz J. L., Counter F. T. Synthesis and antibacterial evaluation of N-alkyl vancomycins. J. Antibiot. 41, 63–72 (1989).
Griffith B. R. et al. Model for antibiotic optimization via neoglycosylation: synthesis of liponeoglycopeptides active against VRE. J. Am. Chem. Soc. 129, 8150–8155 (2007).
Peltier-Pain P., Marchillo K., Andes D. R., Thorson J. S. Natural product disaccharide engineering through tandem glycosyltransferase catalysis reversibility and neoglycosylation. Org. Lett. 14, 5086–5089 (2012).
Arimato H., Nishimura K., Kinumi T., Hayakawa I., Uemura D. Multivalent polymer of vancomycin: enhanced antibacterial activity against VRE. Chem. Commun. 15, 1361–1362 (1999).
Pavlov A. Y., Miroshnikova O. V., Printsevskaya S. S., Olsufyeva E. N., Preobrazhenskaya M. N. Synthesis of hydrophobic N'-mono and N', N"-double alkylated eremomycins inhibiting the transglycosylation stage of bacterial cell wall biosynthesis. J. Antibiot. 54, 455–459 (2001).
Maffioli S. I. et al. Synthesis and antibacterial activity of alkyl derivatives of the glycopeptide antibiotic A40926 and their amides. Bioorg. Med. Chem. Lett. 15, 3801–3805 (2005).
Haldar J., Yarlagadda V., Akkapeddi P. Cationic antibacterial composition. WO Patent 072838 (2013).
Yarlagadda V., Akkapeddi P., Manjunath G. B., Haldar J. Membrane active vancomycin analogues: a novel strategy to combat bacterial resistance. J. Med. Chem. 57, 4558–4568 (2014).
Zhanel G. G. et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 70, 859–886 (2010).
James R. C., Pierce J. G., Okano A., Xie J., Boger D. L. Redesign of glycopeptide antibiotics: back to the future. ACS Chem. Biol. 7, 797–804 (2012).
Xie J., Pierce J. G., James R. C., Okano A., Boger D. L. A redesigned vancomycin engineered for dual D-Ala-D-Ala and D-Ala-D-Lac binding exhibits potent antimicrobial activity against vancomycin-resistant bacteria. J. Am. Chem. Soc. 133, 13946–13949 (2011).
Nitanai Y. et al. Crystal structures of the complexes between vancomycin and cell-wall precursor analogs. J. Mol. Biol. 385, 1422–1432 (2009).
Fekete A., Borbas A., Antus S., Liptak A. Synthesis of 3,6-branched arabinogalactan-type tetra- and hexasaccharides for characterization of monoclonal antibodies. Carbohydr. Res. 344, 1434–1441 (2009).
Blanzat M. et al. New catanionic glycolipids. 1. Synthesis, characterization, and biological activity of double-chain and gemini cationic analogues of galactosylceramide (galβ1cer). Langmuir 15, 6163–6169 (1999).
Thayer D. A., Wong C. H. Vancomycin analogues containing monosaccharides exhibit improved antibiotic activity: a combined one-pot enzymatic glycosylation and chemical diversification strategy. Chem. Asian J. 1, 445–452 (2006).
Sundram U. N., Griffin J. H. General and efficient method for the solution and solid phase synthesis of vancomycin carboxamide derivatives. J. Org. Chem. 60, 1102–1103 (1995).
Wiegand I., Hilpert K., Hancock R. E. W. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat. Protoc. 3, 163–175 (2008).
Draghi D. C. et al. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative. J. Antimicrob. Chemother. 62, 116–121 (2008).
Biedenbach D. J., Bell J. M., Sader H. S., Turnidge J. D., Jones R. N. Activities of dalbavancin against a worldwide collection of 81 673 Gram-positive bacterial isolates. Antimicrob. Agents Chemother. 53, 1260–1263 (2009).
Perkins H. R. Specificity of combination between mucopeptide precursors and vancomycin or ristocetin. Biochem. J. 111, 195–205 (1969).
Nieto M., Perkins H. R. Physicochemical properties of vancomycin and iodovancomycin and their complexes with diacetyl L-lysyl-D-alanyl-D-alanine. Biochem. J. 123, 773–787 (1971).
Crowley B. M., Boger D. L. Total synthesis and evaluation of [Ψ(CH2NH)Tpg4]vancomycin aglycon: reengineering vancomycin for dual D-Ala-D-Ala and D-Ala-D-Lac binding. J. Am. Chem. Soc. 128, 2885–2892 (2006).
Slusarz R., Szulc M., Madaj J. Molecular modeling of Gram-positive bacteria peptidoglycan layer, selected glycopeptide antibiotics and vancomycin derivatives modified with sugar moieties. Carbohydr. Res 389, 154–164 (2014).
Allen N. E., Nicas T. I. Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol. Rev. 26, 511–532 (2003).
Ge M. et al. Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala. Science 284, 507–511 (1999).
Eggert U. S. et al. Genetic basis for activity difference between vancomycin and glycolipid derivatives of vancomycin. Science 294, 361–364 (2001).
Higgins D. L. et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49, 1127–1134 (2005).
Domenech O. et al. Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: effect on membrane permeability and nanoscale lipid membrane organization. Biochim. Biophys. Acta 1788, 1832–1840 (2009).
Allen N. E., LeTourneau D. L., Hobbs J. N. Jr . The role of hydrophobic side chains as determinants of antibacterial activity of semisynthetic glycopeptide antibiotics. J. Antibiot. 50, 677–684 (1997).
Kim S. J., Tanaka K. S., Dietrich E., Rafai Far A., Schaefer J. Locations of the hydrophobic side chains of lipoglycopeptides bound to the peptidoglycan of Staphylococcus aureus. Biochemistry 52, 3405–3414 (2013).
Acknowledgements
We thank Prof CNR Rao (JNCASR) for his constant support and encouragement. JH acknowledges the Department of Science and Technology (DST), Govt. of India for the Ramanujan Fellowship (SR/S2/RJN-43/2009). YV thanks CSIR for the research fellowship.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest. JNCASR has filed a patent application based on the work described in the manuscript.
Additional information
Supplementary Information accompanies the paper on The Journal of Antibiotics website
Supplementary information
Rights and permissions
About this article
Cite this article
Yarlagadda, V., Konai, M., Manjunath, G. et al. Tackling vancomycin-resistant bacteria with ‘lipophilic–vancomycin–carbohydrate conjugates’. J Antibiot 68, 302–312 (2015). https://doi.org/10.1038/ja.2014.144
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/ja.2014.144
This article is cited by
-
Transportan 10 improves the pharmacokinetics and pharmacodynamics of vancomycin
Scientific Reports (2019)
